CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance (Q35116847)

6 August 2017

title

CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance (English)

1 reference

6 August 2017

1 reference

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615685%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615685%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Paul J Cozzi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615685%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Jing L Hao

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615685%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Julia Beretov

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615685%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Lei Chang

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615685%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Wei Duan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615685%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Sarah Shigdar

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615685%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Warick J Delprado

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615685%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Peter H Graham

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615685%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Joseph Bucci

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615685%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

John H Kearsley

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615685%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

language of work or name

1 reference

12 February 2014

1 reference

6 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615685%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615685%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615685%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

page(s)

602-617

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24615685%20AND%20SRC:MED&resulttype=core&format=json

New therapies for castration-resistant prostate cancer: efficacy and safety

9 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Neoadjuvant radiotherapy for locally advanced and high-risk prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Redox regulation in stem-like cancer cells by CD44 variant isoforms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

CD44: structure, function, and association with the malignant process.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: novel post-transcriptional, post-translational regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Expression of mutant p53 protein and CD44 variant proteins in colorectal tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Changing neighbours, changing behaviour: cell adhesion molecule-mediated signalling during tumour progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Expression of CD44 variants and its association with survival in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

CD44 is a biomarker associated with human prostate cancer radiation sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

In vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

CD44 and CD44v6 downregulation in clinical prostatic carcinoma: relation to Gleason grade and cytoarchitecture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Expression and prognostic value of CD44 standard and variant v3 and v6 isoforms in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Relationship between CD44 expression and differentiation of human prostate adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Micrometastases formation: a probabilistic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Role of versican, hyaluronan and CD44 in ovarian cancer metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

The basics of epithelial-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Identification of pancreatic cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Prospective identification of tumorigenic breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Frequency of cells expressing CD44, a Head and Neck cancer stem cell marker: Correlation with tumor aggressiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Bladder cancer initiating cells (BCICs) are among EMA-CD44v6+ subset: novel methods for isolating undetermined cancer stem (initiating) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

CD44v6 Regulates Growth of Brain Tumor Stem Cells Partially through the AKT-Mediated Pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Isolation and in vitro expansion of human colonic stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Identification and characterization of ovarian cancer-initiating cells from primary human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Anchorage-independent culture maintains prostate stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Cell signaling and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

PI3K/Akt signalling pathway and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

PI3K, Erk Signaling in BMP7-Induced Epithelial-Mesenchymal Transition (EMT) of PC-3 Prostate Cancer Cells in 2- and 3-Dimensional Cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Wnt/beta-catenin-pathway as a molecular target for future anti-cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Regulation of human nitric oxide synthase 2 expression by Wnt beta-catenin signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Stem cell origin of cancer and differentiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Transcriptional regulation of livin by beta-catenin/TCF signaling in human lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Prevention of tumor metastasis formation by anti-variant CD44.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Delivery of CD44 shRNA/nanoparticles within cancer cells: perturbation of hyaluronan/CD44v6 interactions and reduction in adenoma growth in Apc Min/+ MICE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775

Suppression of pancreatic tumor growth by targeted arsenic delivery with anti-CD44v6 single chain antibody conjugated nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22775